drugset / Trial / NCT06481371
Zuojin Wan Combined With Rabeprazole or Mosapride for the Treatment of Functional Dyspepsia Combined With Depression
RandomizedParallel-groupSingle-blindBasic science
Summary
To evaluate the symptom improvement of Zuojinwan combined with rabeprazole or Zuojinwan combined with a mosapride regimen in patients with functional dyspepsia combined with depression (liver-stomach depression-heat type) using rabeprazole or mosapride regimen as a control, and to compare the patients' adherence to the medication and the adverse effects between the two groups.
Timeline
- Start
- 2024-06-30
- Primary completion
- 2025-02-27
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mosapride | Small molecule | 5 mg | Oral |
| Subject | Rabeprazole | Small molecule | 20 mg | — |
| Subject | zuojinwan | Unknown | 3 g | — |